Novavax Inc (NASDAQ:NVAX) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Erika Schultz -- Senior Director of Investor Relations John Jacobs -- President and
Novavax Inc.
-(NVAX)
XNAS:NVAX
Novavax Inc (NVAX) Q3 2022 Earnings Call Transcript
Novavax Inc (NASDAQ:NVAX) Q3 2022 Earnings Call dated Nov. 08, 2022. Corporate Participants: Silvia Taylor -- Executive Vice President, Chief Communications Officer Stanley C.
Novavax, Inc. (NVAX) Q4 2021 Earnings Call Transcript
Novavax, Inc. (NASDAQ: NVAX) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Silvia Taylor -- Senior Vice President of Global Corporate Affairs
Earnings calendar for the week of August 2
Labor market conditions improved once again and jobless claims dropped to about 400,000 after rising last week, as economic activity picked up.
Earnings calendar for the week of May 10
Stock markets rallied amid mixed cues on the health of the labor market, with latest data showing that payrolls grew at a
Novavax Inc (NVAX) Q4 2020 Earnings Call Transcript
Novavax Inc (NASDAQ: NVAX) Q4 2020 earnings call dated March. 01, 2021. Corporate Participants: Silvia Taylor -- Senior Vice President, Investor Relations and Corporate
Earnings calendar for the week of March 1
It seems the GameStop saga is far from over, as the company's stock spiked again this week in a movement reminiscent of
Where do these companies stand in the COVID-19 vaccine race?
After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the
Novavax (NVAX) brings its share to the COVID-19 vaccine table; stock soars
Novavax Inc.’s (NASDAQ: NVAX) shares soared 50% in morning hours on Friday after the company announced that its COVID-19 vaccine candidate displayed
Is it time to book profits from Moderna?
Moderna (NASDAQ: MRNA) stock has soared a staggering 679% since the beginning of this year. If you did identify the potential of
Can COVID vaccine be a panacea for Novavax’s (NVAX) growth needs?
The market has been closely following the activities of leading biopharma companies for some time, looking for updates on their COVID vaccine
Earnings calendar for the week of Nov. 9
Taking a cue from the presidential election, stock markets bounced back after ending the previous week on a low note. Major indexes
COVID-19 vaccine development: A look at some of the pharma companies and their progress
The COVID-19 pandemic continues to go on and while the world is slowly coming out of the previously imposed strict lockdown, things
Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2
After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company
Novavax Inc. (NVAX) Q2 2020 Earnings Call Transcript
Novavax Inc (NASDAQ: NVAX) Q2 2020 earnings call dated Aug. 10, 2020 Corporate Participants: Silvia Taylor -- Senior Vice President, Investor Relations and Corporate
Novavax (NVAX) tops Q2 2020 bottom line targets, misses revenue views
Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue jumped to
Fueled by funding, Novavax (NVAX) gains ground in race for Covid-19 vaccine
For Novavax Inc. (NASDAQ: NVAX), the new fiscal year is of great significance due to the progress it has achieved in developing
Novavax Inc. (NASDAQ: NVAX) Q1 2020 Earnings Call Transcript
Novavax Inc. (NVAX) Q1 2020 earnings call dated May 11, 2020 Corporate Participants: Erika Trahan -- Investor Relations Stanley C. Erck -- President and Chief Executive
NVAX Earnings: Key highlights from Novavax Q1 2020 results
Novavax, Inc. (NASDAQ: NVAX) today announced its first quarter financial results for the period ended March 31, 2020. NVAX reported net loss
Novavax (NVAX) posts wider-than-expected loss in Q4
Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower expenses. The
Novavax beats Q1 revenue estimates while earnings come in line
Novavax Inc. (NASDAQ: NVAX) topped market estimates on revenue for the first quarter of 2019 while earnings matched expectations. Analysts had forecasted